help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on November 6, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-0526
A more recent version of this article appeared on December 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/12/4529    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaplan, S. A.
Right arrow Articles by Cohen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaplan, S. A.
Right arrow Articles by Cohen, P.
Related Collections
Right arrow Male Endocrinology
Right arrow Metabolism

Submitted on March 8, 2007
Accepted on October 29, 2007

The Somatomedin Hypothesis 2007: Fifty Years Later

Solomon A. Kaplan* and Pinchas Cohen

David Geffen School of Medicine at UCLA, Los Angeles, CA 90095

* To whom correspondence should be addressed. E-mail: skaplan{at}mednet.ucla.edu.

Context: The somatomedin/insulin-like growth factor (IGF) hypothesis was based on the observation that growth hormone (GH) was inactive when added to an in vitro incubation system but required a GH-dependent substance in the circulation to mediate its activity. Newer experimental evidence has led to several modifications of the hypothesis but none of the proposed modifications accounts for all of the integrated actions of GH and IGF-I. In this paper we propose an augmentative/counteractive modification of the existing hypothesis that takes into account all the actions of the GH-IGF system.

Evidence Acquisition: The modification is based on experimental evidence published since the hypothesis was originally developed.

Evidence Synthesis: The modification is based on an integration of the results of published experimental evidence regarding the actions of GH and the IGF complex.

Conclusion: We propose a new augmentative/counteractive modification of the hypothesis that the actions of the GH-IGF system provide a distinct evolutionary advantage to the organism by augmenting the anabolic actions of GH while countering its potentially deleterious effects of hyperglycemia and depletion of lipid stores.


Key words: somatotropin • IGF • somatomedin • growth




This article has been cited by other articles:


Home page
EndocrinologyHome page
A. C.-M. Chang, J. Hook, F. A. Lemckert, M. M. McDonald, M.-A. T. Nguyen, E. C. Hardeman, D. G. Little, P. W. Gunning, and R. R. Reddel
The Murine Stanniocalcin 2 Gene Is a Negative Regulator of Postnatal Growth
Endocrinology, May 1, 2008; 149(5): 2403 - 2410.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society